Introduction
Tumor cell-microenvironment interactions have been established as critical influences on cell survival in many different cell types. 1, 2 For the most part, studies in this area have focused on the ability of cells to evade apoptosis induced by serum withdrawal or the blocking of adhesion (anoikis). Recently, we demonstrated that a tumor cell's interaction with the ECM component fibronectin (FN) is an important determinant of drug response and may be a critical step in the development of drug-resistant cell populations. 3, 4 Other investigators have since implicated other extracellular matrix (ECM) substrates as influencing drug-induced apoptosis in other cell types. 5 This phenomenon, termed cell adhesion-mediated drug resistance (CAM-DR), is mediated through ␤1 integrins and was discovered using multiple myeloma as a disease model. In this malignancy, neoplastic plasma cells are known to principally reside within the bone marrow compartment where they reside in close contact with bone marrow stromal cells and ECM constituents such as FN. Although the degree of resistance induced by cell adhesion is lower than that seen with many acquired mechanisms of drug resistance (ie P-glycoprotein overexpression), CAM-DR represents a novel intrinsic pathway for evading drug-induced apoptosis. Since even very small surviving tumor fractions (Ͻ1%) have the potential to generate a large drug-resistant cell population after initial treatments, the importance of de novo mechanisms of drug resistance may be greatly underappreciated. In general, highlevel drug resistance mechanisms are not found in the unselected tumor cell population, and de novo resistance mechanisms such as CAM-DR may provide sufficient cytoprotection to allow the emergence of these acquired mechanisms.
Chronic myelogenous leukemia (CML) is a disease in which tumor cells are known to express ␤1 integrins such as VLA-5 and VLA-4. 6, 7 Although CML is characterized by a vast expansion of the malignant cell population in the periphery, leukemic cells can still be found within the tissue of origin, the bone marrow. 8, 9 We sought to determine whether or not integrin-mediated cell adhesion could influence drug response in CML cells and if integrin-mediated signaling converges with the BCR/ABL signaling pathway known to be responsible for the survival of CML cells.
CML is a disease in which the vast majority of patients display a characteristic cytogenetic abnormality known as the Philadelphia (Ph) chromosome. Ph+ CML cells contain a reciprocal translocation between chromosomes 9 and 22 which creates a fusion protein consisting of the BCR (breakpoint cluster region) and the c-Abl proto-oncogene products. This event is sufficient to transform hematopoietic progenitor cells and is generally accepted to be the initiating step in CML. 10, 11 The p210 bcr-abl fusion protein is a constitutively active tyrosine kinase that is also believed to be the main contributor to the inherent resistance of CML cells to almost every chemotherapeutic agent. [12] [13] [14] [15] Antisense oligonucleotides targeted to the BCR/ABL gene have been shown to cause increased apoptosis and the loss of the multidrug-resistant phenotype in K562 CML cells. 12, 16 The exact mechanism of BCR/ABL-mediated drug resistance is not entirely clear and most likely is multi-factorial. Several investigators have implicated PKC and Bcl-Xl as playing at least a partial role in BCR/ABL-mediated drug resistance. 13, 17 The BCR/ABL fusion protein is present in virtually all CML patient tumor specimens and appears to be the initial transforming event. Because of these findings BCR/ABL is an attractive target for the development of potential inhibitors of this constuitively active non-receptor tyrosine kinase. To this end, several classes of inhibitors have been identified, and small molecule inhibitors of BCR/ABL kinase have shown promise as anti-tumor drugs both in vitro and in vivo. [18] [19] [20] Two classes of compounds have been discovered with selectivity towards BCR/ABL. The first class consists of small molecules targeted towards the ATP binding domain of BCR/ABL, 21 and includes a series of 2-phenylaminopyridines with STI-571 emerging as the lead compound. 22, 23 The second class of compounds, the tyrphostins, targets the binding of BCR/ABL peptide subtrates and includes AG957. 24, 25 In addition to the intrinsic anti-tumor activity associated with these compounds, they also may sensitize cells to chemotherapeutic agents, as was shown with the tyrphostin AG957 and STI-571 in K562 cells. 13, 26 Integrin-and BCR/ABL-mediated signal transduction pathways are known to utilize similar kinases and focal adhesion proteins. The chimeric BCR/ABL protein is essentially an unregulated c-Abl tyrosine kinase that initiates a multitude of downstream signaling events in Ph+ cells. It has been shown that adhesion to FN through ␤1 integrins can cause the recruitment of c-Abl from the nucleus to focal adhesions at the plasma membrane where it is phosphorylated and becomes an active kinase. 27, 28 c-Abl-mediated signaling is known to suppress apoptosis induced by glucocorticoids in progenitor B cell lines and v-Abl is sufficient to protect cells from melphalan-and hydroxyurea-induced apoptosis. 29, 30 We questioned whether c-Abl kinase signaling is involved with CAM-DR. Several receptor-proximal signaling proteins are known to be involved with both integrin signaling, as well as BCR/ABL signaling and include focal adhesion kinase (p125FAK), p130Cas, PI-3 kinase, and paxillin. [31] [32] [33] [34] [35] Currently, there are very few, if any, published reports on integrin signaling in CML and it is unknown if ␤1 integrins and BCR/ABL induce signals through common proteins (cross-talk) in cells of this origin.
In this study, we examined the potential of VLA-5 integrin in inducing cell adhesion-mediated drug resistance in K562 CML cells following adhesion to FN. We also assessed the ability of this ␣5␤1 integrin heterodimer to protect cells from apoptosis following inhibition of BCR/ABL. The activation of tyrosine kinases by integrins following blockade of the BCR/ABL pathway was also analyzed.
Materials and methods

Cell culture conditions
The K562 cell line was obtained from the American Type Culture Collection (Rockville, MD, USA). Cells were grown in suspension in RPMI 1640 medium supplemented with 5% fetal bovine serum, 1% (v/v) penicillin (100 units/ml), streptomycin (100 units/ml), and 1% (v/v) l-glutamine (all from Gibco BRL, Grand Island, NY, USA). Cells were maintained at 37°C in 5% CO 2 -95% air atmosphere and subcultured every 6 days.
Materials
All cytotoxic drugs were obtained from Sigma-Aldrich (St Louis, MO, USA) and were dissolved in H 2 O except for melphalan (LPAM), which was dissolved in acidified ethanol. BCR/ABL kinase inhibitor AG957 was from Calbiochem (San Diego, CA, USA) and was solubilized in DMSO. STI-571 was obtained from Novartis Pharmaceuticals (East Hanover, NJ, USA) and was solubilized in DMSO. Radiation exposure was carried out in a Mark I model 68A irradiator using a 2200 Ci 137 Cs source. Anti-CDw49d (␣ 4 ) mAb P4G9, anti-CDw49e (␣ 5 ) mAb P1D6, and FITC-conjugated goat-anti-mouse antibodies were all from DAKO (Carpinteria, CA, USA). Anti-CD29 mAb MAR4 (for ␤1 expression analysis) was obtained from Pharmingen (San Diego, CA, USA). ␤1 blocking Ab P4C10 was from Life Technologies (Rockville, MD, USA). Anti-phosphotyrosine mAb (4G10) was from Upstate Biotechnology (Lake Placid, NY, USA). Anti-␤-actin mAb was from Sigma. HRP-conjugated goat-anti-mouse and goat-anti-rabbit Leukemia antibodies were from Jackson Immunoresearch (West Grove, PA, USA).
MTT cytotoxicity assays
Assays were performed as previously described 3 except that 2 × 10 4 (K562) cells were initially seeded in each FN-coated well and 8 × 10 3 (K562) cells were added to BSA-coated wells (suspension control). Following 2 h of adhesion in serum-free media, non-adherent cells were removed from FN wells with three washes and RPMI media containing 10% FBS were added to each well. Suspension cells were also placed in serum-free media for 2 h prior to centrifugation and addition of RPMI media containing 10% FBS. Following an additional 24 h of cellular adhesion, each well was exposed to drug for 90 min or 96 h (continuous exposure). IC 50 values were calculated by linear regression analysis of % survival vs drug concentration.
Annexin V apoptosis analysis
For each replicate, 1 × 10 6 cells were attached to 35 mm dishes (Nunc, Rochester, NY, USA) coated overnight with 1 ml of 40 g/ml FN. In some experiments, cells were pre-incubated with either an ␣4 or ␣5 blocking antibody for an additional 15 min prior to attachment. After 2 h, non-adhered cells were removed from plates with serum-free medium washes. Cells were exposed to drug for 90 min (plus a 24 h drug-free incubation period) or for 24 h continuously. As a control, 0.4 × 10 6 cells (approximately equal to the number of cells adhered to FN) were drug-treated in suspension and then seeded on uncoated 35 mm dishes. Cells were then collected using gentle agitation and were incubated with FITC-conjugated Annexin V (BioVision, Palo Alto, CA, USA). Five thousand to 10 000 events were analyzed on a FACScan machine (Becton Dickinson, San Jose, CA, USA) and % apoptosis was determined using CellQuest software (Becton Dickinson).
Integrin functional analysis
To assess integrin binding ability, a colorimetric cell adhesion assay was utilized. For each replicate, 1.5 × 10 5 cells were adhered to FN-or BSA-coated 96-well plates for 90 min in serum-free RPMI and were analyzed as described previously. 3 In some experiments, cells were pre-incubated for 15 min with P1D6 (anti-␣5), P4C10 (anti-␤1), P4G9 (anti-␣ 4 ), or isotype antibody controls prior to application to wells to determine specific subunit contribution to FN adhesion.
Western blot analysis
Approximately 5 × 10 6 cells were adhered to 60 mm FNcoated plates (prepared as previously described, except that 3 ml of 40 g/ml FN was used) in serum-free RPMI. Control cells were kept in serum-free media (at an equal density) for a period of time equal to the adhesion time. Non-adherent cells were gently washed two to three times with serum-free media and cells were placed back into media containing 5% FBS. Cells were lysed in ice-cold modified RIPA buffer (50 mm Tris-HCl pH 7.5, 150 mm NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) containing fresh protease and phos-phatase inhibitors (2 g/ml aprotinin, 2 g/ml leupeptin, 2 mm PMSF, 20 mm NaF, 1 mm sodium vanadate, 10 mm sodium pyrophosphate, 20 mm ␤-glycerophosphate). Cells were lysed for 20 min, then centrifuged for 5 min at 14 000 r.p.m. in a microfuge at 4°C; lysates were quantitated using the BCA protein assay (Pierce, Rockford, IL, USA). Equivalent amounts of protein were separated by 10% or 12% SDS-PAGE, transferred to PVDF membrane (Bio-Rad, Richmond, CA, USA) overnight, and blocked in PBS containing 5% dry milk and 0.1% Tween-20 (Bcl-2 family and ␤-actin immunoblotting) or PBS containing 3% milk for 2 h (phosphotyrosine immunoblotting). Membranes were incubated with primary antibodies, washed, and then incubated with HRP-conjugated secondary antibodies. Proteins were visualized using Lumi-Light substrate (Boehringer Mannheim, Indianapolis, IN, USA) and X-ray film (Kodak, Rochester, NY, USA). To assay for equal protein loading, membranes were stripped for 30 min at 50°C in stripping buffer (62.5 mm Tris-HCl pH 6.8, 2% SDS, 100 mm 2-mercaptoethanol), re-blocked, and probed with anti-␤-actin mAb.
Results and discussion
K562 cells are resistant to drug-induced apoptosis when adhered to FN
Previous reports have established that myeloma cells adhered to FN are resistant to drug-induced apoptosis and that small cell lung cancer cells adhered to FN, collagen, and laminin are also resistant to cytotoxic agents. [3] [4] [5] In this study, we investigated whether tumor cell-ECM interactions are also critical determinants in the survival of chronic myelogenous leukemia cells. The MTT assay was used to detect differences in the drug sensitivity of FN adhered vs suspension-cultured cells following a 90 min or 96 hr (continuous) exposure to either mitoxantrone or melphalan (l-phenylalanine mustard or LPAM). After a 96 h incubation period, cell survival was determined by the MTT assay. Figure 1a and b depict representative continuous exposure experiments using mitoxantrone and LPAM, respectively. Table 1 summarizes IC 50 values, standard deviations, and degree of resistance from several experiments. In addition to the MTT assay, cell survival was analyzed using an annexin V flow cytometric based assay (Table 2) . In these assays, K562 cells adhered to FN were found to be significantly resistant to apoptosis induced by a number of DNA damaging agents including LPAM, mitoxantrone, and ␥-irradiation. Significant cytoprotection was primarily observed for DNA damaging agents as compared to the microtubule inhibitor vincristine. Vincristine and Ara-C were only used in continuous exposure experiments due to the inherent insensitivity of K562 cells to these compounds. As controls, neither non-specific, charge-based adhesion to polyl-lysine nor exposure to bovine serum albumin (BSA) caused resistance to cytotoxic drugs (Figure 2 ). In addition, soluble FN added to culture medium did not provide a survival advantage to drug-treated cells (data not shown). These results indicate a requirement for both receptor occupancy by FN and physical attachment by the cell in order for cell adhesionmediated drug resistance to occur.
Contribution of ␣5 to CAM-DR in K562
The ability of K562 cell lines to adhere to FN through various integrin subunits was determined using a colorimetric cell adhesion assay and function-blocking antibodies to ␤1, ␣4 and ␣5. As shown in Figure 3a , K562 cells adhere to FN solely through VLA-5.
In order to determine the specificity of ␣5 contributing to the CAM-DR phenotype, K562 cells were analyzed for sensitivity to melphalan following preincuabtion with an ␣5 blocking antibody. As can be seen in Figure 3b , when incubated with ␣4 blocking antibody prior to FN adhesion, K562 cells continued to demonstrate protection against melphalaninduced apoptosis (30.1 ± 1.5% protection for isotype control vs 28.4 ± 1.5% protection for ␣4 blocking antibody). In contrast, when incubated with ␣5 blocking antibody prior to adhesion, K562 became sensitive to melphalan exposure (0 ± 11.1% protection). It can therefore be concluded that the FN-induced cytoprotection observed with K562 cells is dependent on ␣5␤1-mediated adhesion.
FN-adhered K562 cells are resistant to apoptosis induced by BCR/ABL kinase inhibition
There is conflicting evidence pertaining to the effects of BCR/ABL on integrin function. Bazzoni et al 36 reported that BCR/ABL kinase activity increased the ligand binding efficiency of integrins expressed by a number of hematopoietic cell lines and that precursor cells from patients with CML Ara-C 100 M cont. 11.3 ± 5.5
6.2 ± 1.6* 54.9 exp.
XRT 5000 rads 32.3 ± 5.5 26.4 ± 3.6* 81.7
Cells were treated as described in Figure 2 . Percent control death = FN mean death/Sus mean death. *Denotes P Ͻ 0.05 by a one-tailed Student's t-test. Each experiment was repeated at least three times in replicates of two.
Figure 2
K562 cells are resistant to melphalan-induced apoptosis only when adhered to FN. Cells were seeded on each matrix for 2 h, exposed to 100 m LPAM for 90 min, washed, and incubated for 24 h. Percent apoptosis was determined by annexin V staining and flow cytometry, during which 5000 events were analyzed for each sample. Bars represent standard deviations and * denotes significant reduction in apoptosis by a one-tailed Student's t-test (P Ͻ 0.05).
Leukemia
Figure 3
VLA-5 (␣5␤1 integrin) mediates K562 FN adhesion and CAM-DR. Cell adhesion was determined using a colorimetric assay in conjunction with integrin blocking antibodies (a). Cells were pretreated with blocking mAb prior to application to FN-coated wells for 1 h. Absorbance values shown are the mean of three replicates, with background binding to BSA subtracted from each. Experiments were repeated three times. Treatment of cells with ␣5 blocking antibody reverses CAM-DR phenotype (b). Cells were pretreated with anti-␣4 blocking mAb (P4G9), anti-␣5 blocking mAb (P1D6), or IgG3 isotype control Ab prior to adhesion to FN-coated dishes. Cells were exposed to 100 m LPAM for 90 min, washed, incubated for 24 h, and analyzed using annexin V staining and flow cytometry. The percent protection was calculated as follows: (% apoptosis FN adhered/% apoptosis suspension) × 100. Bars are the standard deviations of three independent experiments performed in duplicate.
showed increased adhesion to FN compared to normal controls. Conversely, Bhatia et al 37 reported that inhibition of the BCR/ABL kinase led to increased adhesion of CML cells to stroma and FN. Our own cell adhesion assays have shown that BCR/ABL inhibition by relatively high doses of the tyrphostin AG957 can have negative effects on FN adhesion (data not shown). At the concentrations of inhibitor used in the preceding apoptotic assays, the adhesion of K562 cells to FN was not affected by more than 20-40%.
The BCR/ABL kinase is believed to be critical to the survival of CML cells through its effects on a number of signal transduction pathways. Inhibitors of this fusion protein have shown promise as apoptosis-inducing drugs in CML cells and are now being used in clinical trials. 20, 38 As shown in Figure 4 , cellular adhesion to FN inhibited apoptosis induced by two mechanistically distinct BCR-ABL tyrosine kinase inhibitors. Recent evidence suggests that following chronic drug exposure, resistance to STI-571 can occur via multiple mechanisms including increased BCR/ABL mRNA and protein lev- K562 cells adhered to FN are resistant to apoptosis induced by the BCR/ABL inhibitors STI-571 and AG957. Cells were adhered to FN for 24 h prior to the addition of either varying concentrations of STI-571 (a) or 10 m AG957 (b). Following 48 h of continuous drug treatment, apoptotic cells were identified by annexin V staining as described in the Materials and methods section. Each data point is the mean of two to three independent experiments performed in duplicates. els, as well as overexpression of the multi-drug transporter Pgp. 39, 40 We previously reported that the CAM-DR phenotype was not the result of decreased drug accumulation and thus it is unlikely that the resistance associated with STI-571 treatment is due to decreased intracellular drug concentration. 3 These results suggested that signaling events initiated by cellular adhesion to FN may overlap survival signals induced by the activation of BCR/ABL signal transduction pathway(s).
BCR/ABL-associated tyrosine kinase activity is not reconstituted by integrin-mediated signaling
The preceding observations presented the possibility that integrins, at least in the K562 cell line, may signal through tyrosine kinases similar to those activated by BCR/ABL, effectively reconstituting the survival pathway inhibited by STI-571 and AG957. In some instances, when activated through FN adhesion, integrins are known to mimic many of the aspects of BCR/ABL signaling through the recruitment of c-Abl. 27, 28 Proteins such as p125FAK, p130Cas, paxillin, and PI3-kinase have repeatedly been shown to be activated (through tyrosine phosphorylation) by both BCR/ABL and ␤1 integrins independently. 34, 35 It was therefore possible that FN adhesion allowed K562 cells to survive BCR/ABL inhibition by substituting as Adhesion of K562 cells to FN causes increased tyrosine phosphorylation of an 80 kDa protein. Cells were adhered to FN for the times indicated or were kept in suspension, then analyzed for the presence of phosphorylated tyrosine residues. Western blotting using anti-phosphotyrosine mAb was used to determine activity and ␤-actin was used as a control for equal protein loading.
Figure 6
Integrin activation does not reconstitute BCR/ABL-associated tyrosine kinase activity in AG957-treated cells. K562 cells were adhered to FN or kept in suspension for 24 h, after which they were exposed to 20 m AG957 or DMSO (vehicle control) for 4 h. Proteins were separated by 10% SDS-PAGE and subjected to anti-phosphotyrosine immunoblotting. AG957 abrogated all phosphotyrosine activity with the exception of the 80 kDa protein, which persisted to a lesser degree. Blot shown is representative of three independent experiments.
the initiator of this survival pathway. A temporal analysis of phosphotyrosine containing proteins by Western blotting showed an increase in tyrosine phosphorylation of an unknown 80 kDa protein ( Figure 5 ). Additionally, it was discovered that the tyrosine phosphorylation pattern induced by the BCR/ABL kinase was completely abrogated by AG957 in both suspension and FN adhered cells (Figure 6 ), indicating that integrin ligation was providing a survival signal independent or downstream of this group of signaling proteins. This inhibition was achieved using AG957 concentrations similar to those previously described to be sufficient to completely abolish the kinase activity of BCR/ABL in this cell line. 41 A protein band of approximately 80 kDa was activated by FN adhesion and persisted, to a lesser degree, in AG957-treated cells. Whether or not this unknown protein is involved in protecting K562 cells from chemotherapeutic agents or BCR/ABL inhi-bition remains to be determined. Although these experiments rule out the integrin-induced activation of focal adhesion proteins such as FAK (125 kDa), p130Cas (125 and 115 kDa), paxillin (65 kDa) and c-Abl (145 kDa), other ␤1 integrin-activated proteins that would not be detected by phosphotyrosine analysis, such as serine/threonine phosphorylated proteins, may be contributing to the CAM-DR phenotype.
FN-adhered K562 cells maintain the CAM-DR phenotype during AG957 exposure
With the exception of an unknown 80 kDa protein, FNadhered cells did not induce noticeable tyrosine phosphorylation following AG957 treatment ( Figure 6 ). We also examined whether FN-adhered cells would remain resistant to drug-induced apoptosis following AG957 exposure. Cells were adhered to FN or kept in suspension for 3 h, then exposed to AG957 (10 or 20 m) or DMSO vehicle control for 1 h, and then treated with 100 m LPAM or vehicle control for 90 min. Apoptosis was analyzed by annexin V staining 24 h later, as described previously. As can be seen in Figure 7 , the CAM-DR phenotype is maintained even when FN adhesion is followed by AG957 treatment. Integrin activation was sufficient to protect K562 cells from the BCR/ABL inhibitor alone (AG957 + Acid-OH controls) and in combination with the alkylating agent, melphalan (AG957 + LPAM). These results further support the finding that integrin-induced cytoprotection to DNA damaging agents is mediated through signaling events independent of the tyrosine kinases activated by BCR/ABL.
␥-Irradiation and drugs such as melphalan, mitoxantrone, and AG957 are known to induce apoptosis through different means. The ability of ␤1 integrins to protect cells from apoptosis induced by such a wide range of functionally distinct agents suggests a block in the initiation or execution of apoptosis at a point of general convergence. The Bcl-2 family FN-adhered cells maintain the CAM-DR phenotype during AG957 exposure. K562 cells were adhered to FN (striped bars) or kept in suspension (solid bars) for 3 h, treated with AG957 (or DMSO vehicle control) for 2 h, then exposed to 100 m LPAM (or Acid-OH vehicle control) for 90 min. Apoptosis was analyzed 24 h later by annexin V staining and flow cytometry. Graph is representative of three independent experiments performed in duplicate. Statistically significant differences in % apoptosis (FN vs suspension) are indicated by *(P Ͻ 0.05 by one-tailed Student's t-test).
of proteins fits the profile of general regulators of apoptotic commitment and these proteins have been reported to be affected by integrin activation. 42 An RNase protection assay demonstrated no consistent changes in the levels of RNA pertaining to any one of the Bcl-2 family member genes in FNadhered K562 cells (data not shown). In addition, the protein levels of Bcl-2, Bcl-Xl, Bax, and Mcl-1 were not altered by FN adhesion in K562 cells (data not shown). These results are consistent with our findings reported for the RPMI 8226 myeloma cell line. 3 Although the exact mechanism mediating CAM-DR remains elusive, it seems to be independent of many known focal adhesion proteins and inhibitors of apoptosis.
A report by Lundell et al 43 demonstrated that CML progenitor cells and K562 cells display a decreased proliferative index when adhered to FN. We also observed that myeloma cells adhered to FN caused inhibition of cell cycle progression. 44 However, it is yet unknown if FN-induced inhibition of cell cycle progression contributes to protection from apoptosis induced by BCR-ABL inhibitors.
The ECM protein FN has been found to play a key role in the survival of a number of hematopoietic cell lines under conditions of cytotoxic stress. CML cells remaining in contact with the bone marrow may form the basis of a tumor cell population that is resistant to the apoptosis-inducing effects of chemotherapy. Consequently, the resistant phenotype induced by integrin ligation would seemingly be applicable to CML cells found in both the chronic and blast phases of this disease. In vitro, the CAM-DR phenotype also allows cells to survive the apoptosis-inducing actions of AG957, a specific inhibitor of the BCR/ABL kinase. 41 AG957 was able to disrupt the tyrosine phosphorylation of all proteins activated by the BCR/ABL kinase in K562 cells at relatively low concentrations, resulting in cell death. Integrin activation, despite providing protection against BCR/ABL inhibition, did not reverse the inhibition of phosphorylation of any of these proteins. Finally, it was determined that FN-adhered K562 cells remained resistant to melphalan following AG957 exposure, further indicating that the mechanism of CAM-DR is independent of proteins within the BCR/ABL cell survival pathway. In conclusion, adhesion mediated by ␣5␤1 integrin induces drug resistance in K562 CML cells, as well as other hematopoietic cell lines. 3 Small molecule antagonists against the ␤1 integrin subunit may be capable of suppressing the emergence of resistance to BCR/ABL inhibitors and other cancer treatments.
